2009
DOI: 10.1097/iop.0b013e31819946c4
|View full text |Cite
|
Sign up to set email alerts
|

High Versus Low Concentration Botulinum Toxin A for Benign Essential Blepharospasm: Does Dilution Make a Difference?

Abstract: Compared with the control, the high concentration botulinum toxin A demonstrated a 58% reduction in perceived pain. Patients did not report a significant difference in efficacy or complications with either dilution.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(10 citation statements)
references
References 24 publications
(22 reference statements)
0
10
0
Order By: Relevance
“…Both animal and human studies indicate that more extensive dilution enhances the efficacy of each U of toxin by increasing the volume administrated and thereby the extent of diffusion [204][205][206]. However, other studies, including two on children with spastic CP [207,208], have concluded that the efficacy is independent of dilution [207,209,210]. Injection of larger volumes can be more painful and has been reported to give more side-effects due to the spread of toxin to nearby muscles [207,210].…”
Section: Paper Vmentioning
confidence: 99%
“…Both animal and human studies indicate that more extensive dilution enhances the efficacy of each U of toxin by increasing the volume administrated and thereby the extent of diffusion [204][205][206]. However, other studies, including two on children with spastic CP [207,208], have concluded that the efficacy is independent of dilution [207,209,210]. Injection of larger volumes can be more painful and has been reported to give more side-effects due to the spread of toxin to nearby muscles [207,210].…”
Section: Paper Vmentioning
confidence: 99%
“…Clinical studies in spasticity suggest that higher BT doses result in greater clinical effect [35][36][37][38], but also increase adverse events and unwanted effect in adjacent muscles [35][36][37]. Information on the impact of dilution for spasticity [4,[7][8][9][10][11], dilution in other BT indications [39][40][41][42], and BT movement into adjacent muscles for nonÀspasticity-related injections is mixed [43][44][45]. In summary, animal and human data are inconclusive in characterizing BT distribution within muscle after injection, as well as factors associated with that distribution.…”
Section: Introductionmentioning
confidence: 99%
“…Effective duration time is a vital factor that limits the clinical applications of BoNT/A. There have been several attempts to prolong the duration of BoNT/A effect, including usage of higher dosages, high-volume preparation, and electrical stimulation post-injection (Dressler, 2004;Rha et al, 2008;Boyle et al, 2009;Hu et al, 2009). However, the results of these approaches were unsatisfactory.…”
Section: Discussionmentioning
confidence: 99%